share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股sec公告 ·  06/18 07:02
Moomoo AI 已提取核心訊息
On June 17, 2024, Clene Inc. presented a poster at the 2024 ENCALS Meeting, detailing clinical results from the HEALEY ALS Platform Trial open label extension for amyotrophic lateral sclerosis (ALS) treatment with CNM-Au8. The poster, referred to as Exhibit 99.1, was furnished as part of Clene's Form 8-K current report but is not considered filed under the Securities Exchange Act nor incorporated by reference into any of Clene's filings. Additionally, on June 18, 2024, Clene issued a press release, filed as Exhibit 99.2, announcing the presentation of extended survival data through 3.5 years and new neurofilament light (NfL) responder results from the same trial at the ENCALS Meeting.
On June 17, 2024, Clene Inc. presented a poster at the 2024 ENCALS Meeting, detailing clinical results from the HEALEY ALS Platform Trial open label extension for amyotrophic lateral sclerosis (ALS) treatment with CNM-Au8. The poster, referred to as Exhibit 99.1, was furnished as part of Clene's Form 8-K current report but is not considered filed under the Securities Exchange Act nor incorporated by reference into any of Clene's filings. Additionally, on June 18, 2024, Clene issued a press release, filed as Exhibit 99.2, announcing the presentation of extended survival data through 3.5 years and new neurofilament light (NfL) responder results from the same trial at the ENCALS Meeting.
2024年6月17日, Clene Inc.在2024 ENCALS 會議上展示了一份海報,展示了關於使用CNM-Au8治療肌萎縮性側索硬化症(ALS)的HEALEY ALS平台試驗開放標籤擴展的臨床成果。該海報稱爲Exhibit 99.1,作爲Clene的8-K表中的一部分提供,但不被視爲證券交易法案的文件或被引入Clene的任何文件中。此外,2024年6月18日,Clene發佈了新聞稿,作爲Exhibit 99.2提交,宣佈在ENCALS會議上展示了爲期3.5年的延長生存數據和同一試驗的新的神經酸性纖維輕(NfL)反應者結果。
2024年6月17日, Clene Inc.在2024 ENCALS 會議上展示了一份海報,展示了關於使用CNM-Au8治療肌萎縮性側索硬化症(ALS)的HEALEY ALS平台試驗開放標籤擴展的臨床成果。該海報稱爲Exhibit 99.1,作爲Clene的8-K表中的一部分提供,但不被視爲證券交易法案的文件或被引入Clene的任何文件中。此外,2024年6月18日,Clene發佈了新聞稿,作爲Exhibit 99.2提交,宣佈在ENCALS會議上展示了爲期3.5年的延長生存數據和同一試驗的新的神經酸性纖維輕(NfL)反應者結果。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息